Clinical trials
Phase 4 Influenza, Human trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 29 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Insight Therapeutics, LLC | 3 |
| National Cheng-Kung University Hospital | 2 |
| Capital Medical University | 1 |
| Catholic Kwandong University | 1 |
| Centers for Disease Control and Prevention, China | 1 |
| China National Biotec Group Company Limited | 1 |
| Hospices Civils de Lyon | 1 |
| Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited | 1 |
| International Centre for Diarrhoeal Disease Research, Bangladesh | 1 |
| Jiangsu Province Centers for Disease Control and Prevention | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Influenza, Human | 29 |
| Acute Coronary Syndrome | 1 |
| Antiphospholipid Syndrome | 1 |
| Arthritis, Juvenile | 1 |
| Arthritis, Rheumatoid | 1 |
| COVID-19 | 1 |
| Common Cold | 1 |
| Dermatomyositis | 1 |
| HIV Seropositivity | 1 |
| Heart Failure | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.